



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/554,704		
		Filing Date	October 27, 2005		
		First Named Inventor	Olivier Bezencon		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	A0345.0016

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/NR/	AA	US-5,380,758			
/NR/	AB	US-5,703,073			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/NR/	BA	WO-97/27749	08-07-1997	Nitromed Inc.		
/NR/	BB	WO-98/19672	05-14-1998	Nitromed Inc.		
/NR/	BC	WO-98/21193	05-22-1998	Nicox S.A.		
/NR/	BD	WO-99/00361	01-07-1999	Nicox S.A.		
/NR/	BE*	WO-97/09311				
/NR/	BF*	WO-03/093267				
/NR/	BG*	WO-04/002957				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/NR/	CA	Eiji Nakayama, et al., "STUDIES ON ORALLY ACTIVE CEPHALOSPORIN ESTERS," The Journal of Antibiotics, (1990), pp. 1122-1130	
/NR/	CB	Shigeru Oae, et al., "ORGANIC THIONITRITES AND RELATED SUBSTANCES," Organic Preparations and Procedures Int., (1983), pp. 165-198	
/NR/	CC	Daniel L. Comins, et al., "REGIOSPECIFIC $\alpha$ -ALKYLATION OF 4-CHLORO(BROMO)PYRIDINE," J. Org. Chem., (1985), pp. 4410-4411	
/NR/	CD*	Waerber B., et al., "THE RENIN-ANGIOTENSIN SYSTEM IN EXPERIMENTAL AND HUMAN HYPERTENSION", in Berkenhager W.H. Reid J.L. (eds): Hypertension, Amsterdam, Elsevier Science Publishing Co., (1996), pp. 489-519	
/NR/	CE*	Weber, M.A., Am. J. Hypertens., (1992), 5, 247S	
/NR/	CF*	Rosenberg, M.E., et al., Kidney International, (1994), 45, 403	
/NR/	CG*	Breyer, J.A., et al., Kidney International, (1994), 45, S156	
/NR/	CH*	Vaughan, D.E., et al., Cardiovasc. Res., (1994), 28, 159	
/NR/	CI*	Fouad-Tarazi, F., et al., Am. J. Med., (1988), 84 (Suppl. 3A), 83	
/NR/	CJ*	Pfeffer, M.A., et al., N. Engl. J. Med., (1992), 327, 669	
/NR/	CK*	Kleinert, H.D., Cardiovasc. Drugs, (1995), 9, 645	
/NR/	CL*	Husain, A., J. Hypertens., (1993), 11, 1155	
/NR/	CM*	Israilli Z.H., et al., Annals of Internal Medicine, (1992), 117, 234	
/NR/	CN*	Azizi M., et al., J. Hypertens., (1994) 12, 419	
/NR/	CO*	Neutel, J.M., et al., Am. Heart, (1991), 122, 1094	
Examiner Signature	/Niloofer Rahmani/		Date Considered 12/26/2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/554,704
				Filing Date	October 27, 2005
				First Named Inventor	Olivier Bezencon
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	A0345.0016

/NR/	CP*	Rahuel, Jr., et al., Chem. Biol., (2000), 7, 493	
/NR/	CQ*	Mealy, N.E., Drugs of the Future, (2001) 26, 1139	
/NR/	CR*	Oefner, C., et al., Chem. Biol., (1999), 6, 127	
/NR/	CS*	Marki, H.P., et al., Il Farmaco, (2001), 56, 21	
/NR/	CT*	Majewski, M., et al., J. Org. Chem., (1995) 60, 5825	
/NR/	CU*	Kiesewetter, D.O., Tetrahedron Asymmetry, (1993) 4, 2183	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Niloofar Rahmani/	Date Considered	12/26/2007
--------------------	--------------------	-----------------	------------